Header Logo

Connection

ALEXANDER LAZAR to Disease-Free Survival

Back to Details
This is a "connection" page, showing publications ALEXANDER LAZAR has written about Disease-Free Survival.
ALEXANDER LAZAR
Connection Strength
0.503
Disease-Free Survival
  1. Sarcoma Brain Metastases: 28?Years of Experience at a Single Institution. Ann Surg Oncol. 2016 12; 23(Suppl 5):962-967.
    View in: PubMed
    Score: 0.059
  2. Angiosarcoma: a tissue microarray study with diagnostic implications. Am J Dermatopathol. 2013 Jun; 35(4):432-7.
    View in: PubMed
    Score: 0.047
  3. Sarcoma metastases to the skin: a clinicopathologic study of 65 patients. Cancer. 2012 Jun 01; 118(11):2900-4.
    View in: PubMed
    Score: 0.042
  4. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. Am J Clin Oncol. 2019 10; 42(10):744-748.
    View in: PubMed
    Score: 0.018
  5. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol. 2019 Sep; 120(3):382-388.
    View in: PubMed
    Score: 0.018
  6. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 03; 139(3):728-731.
    View in: PubMed
    Score: 0.017
  7. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.017
  8. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. Int J Gynecol Cancer. 2018 09; 28(7):1297-1310.
    View in: PubMed
    Score: 0.017
  9. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res. 2018 10 01; 24(19):4865-4873.
    View in: PubMed
    Score: 0.017
  10. Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res. 2018 09 01; 24(17):4119-4125.
    View in: PubMed
    Score: 0.017
  11. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.016
  12. Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. Histopathology. 2018 Jan; 72(2):239-247.
    View in: PubMed
    Score: 0.016
  13. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 11; 18(11):1493-1501.
    View in: PubMed
    Score: 0.016
  14. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017 09 19; 7(1):11836.
    View in: PubMed
    Score: 0.016
  15. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
    View in: PubMed
    Score: 0.016
  16. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumours. Histopathology. 2017 May; 70(6):946-953.
    View in: PubMed
    Score: 0.015
  17. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.015
  18. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg. 2016 Apr; 151(4):347-54.
    View in: PubMed
    Score: 0.014
  19. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol. 2015 Nov; 22(12):3913-20.
    View in: PubMed
    Score: 0.013
  20. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.013
  21. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013 Sep 03; 109(5):1085-92.
    View in: PubMed
    Score: 0.012
  22. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013 Jul; 20(7):2364-72.
    View in: PubMed
    Score: 0.011
  23. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012 Jun; 227(2):223-33.
    View in: PubMed
    Score: 0.011
  24. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother. 2012 Jul; 61(7):1113-24.
    View in: PubMed
    Score: 0.011
  25. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer. 2009 Jul 01; 115(13):2971-9.
    View in: PubMed
    Score: 0.009
  26. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009 Jun; 249(6):1014-22.
    View in: PubMed
    Score: 0.009
  27. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis. 2008; 25(3):191-9.
    View in: PubMed
    Score: 0.008
  28. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res. 2006 Nov 15; 12(22):6709-15.
    View in: PubMed
    Score: 0.007
  29. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin. 2006 Sep-Oct; 56(5):282-91; quiz 314-5.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.